Literature DB >> 33887352

Correlates of analog vs human basal insulin use among individuals with type 2 diabetes: A cross-sectional study.

Sara J Cromer1, Deborah J Wexler2, Pooyan Kazemian3.   

Abstract

BACKGROUND: Given the shift from use of less expensive human to costlier analog insulins for treatment of type 2 diabetes (T2D), we examine characteristics and glycemic control associated with type of basal insulin use.
METHODS: We analyzed respondents with T2D in six consecutive National Health and Nutrition Examination Survey (NHANES) cycles (2005-2016). Logistic regression models examined associations between demographics, socioeconomic factors, and NHANES cycle with (1) type of basal insulin use and (2) hemoglobin A1c <8.0% and <7.0% according to basal insulin type.
FINDINGS: Basal insulin use increased from 9.6% to 17.2% of respondents with T2D between 2005 and 2016. Among 723 respondents meeting inclusion criteria, the proportion using analog basal insulin rose from 58% to 88%. African American (aOR 0.42, 95% CI 0.24-0.74) and Hispanic (aOR 0.54, 95% CI 0.30-0.96) respondents had lower odds of analog basal insulin use than non-Hispanic White respondents in adjusted and unadjusted models. Older age and having health insurance, but not type of basal insulin use, associated with meeting HbA1c targets.
INTERPRETATION: Non-White NHANES respondents were less likely to use analog basal insulin than White respondents. Increased analog basal insulin use between 2005 and 2016 was not associated with improved glycemic control.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Basal insulin; Health disparity; Type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33887352      PMCID: PMC8217374          DOI: 10.1016/j.diabres.2021.108825

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  28 in total

1.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Authors:  H Yki-Järvinen; A Dressler; M Ziemen
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Authors:  Kjeld Hermansen; Melanie Davies; Taudeusz Derezinski; Gabrielle Martinez Ravn; Per Clauson; Philip Home
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

3.  Racial-ethnic disparities in management and outcomes among children with type 1 diabetes.

Authors:  Steven M Willi; Kellee M Miller; Linda A DiMeglio; Georgeanna J Klingensmith; Jill H Simmons; William V Tamborlane; Kristen J Nadeau; Julie M Kittelsrud; Peter Huckfeldt; Roy W Beck; Terri H Lipman
Journal:  Pediatrics       Date:  2015-03       Impact factor: 7.124

4.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

5.  Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.

Authors:  H Yki-Järvinen; R Kauppinen-Mäkelin; M Tiikkainen; M Vähätalo; H Virtamo; K Nikkilä; T Tulokas; S Hulme; K Hardy; S McNulty; J Hänninen; H Levänen; S Lahdenperä; R Lehtonen; L Ryysy
Journal:  Diabetologia       Date:  2006-02-03       Impact factor: 10.122

6.  A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

Authors:  M Massi Benedetti; E Humburg; A Dressler; M Ziemen
Journal:  Horm Metab Res       Date:  2003-03       Impact factor: 2.936

7.  Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study.

Authors:  Carolyn A Paris; Giuseppina Imperatore; Georgeanna Klingensmith; Diana Petitti; Beatriz Rodriguez; Andrea M Anderson; I David Schwartz; Debra A Standiford; Catherine Pihoker
Journal:  J Pediatr       Date:  2009-04-24       Impact factor: 4.406

8.  Cost-effectiveness of insulin analogues for diabetes mellitus.

Authors:  Chris G Cameron; Heather A Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

Review 9.  Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

Authors:  K Horvath; K Jeitler; A Berghold; S H Ebrahim; T W Gratzer; J Plank; T Kaiser; T R Pieber; A Siebenhofer
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

10.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetes Care       Date:  2018-10-04       Impact factor: 19.112

View more
  1 in total

1.  Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020.

Authors:  Sudipa Sarkar; James Heyward; G Caleb Alexander; Rita R Kalyani
Journal:  JAMA Netw Open       Date:  2021-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.